Unknown

Dataset Information

0

Regulatory T cells and TLR9 activation shape antibody formation to a secreted transgene product in AAV muscle gene transfer.


ABSTRACT: Adeno-associated viral (AAV) gene delivery to skeletal muscle is being explored for systemic delivery of therapeutic proteins. To better understand the signals that govern antibody formation against secreted transgene products in this approach, we administered an intramuscular dose of AAV1 vector expressing human coagulation factor IX (hFIX), which does not cause antibody formation against hFIX in C57BL/6 mice. Interestingly, co-administration of a TLR9 agonist (CpG-deoxyoligonucleotide, ODN) but not of lipopolysaccharide, caused a transient anti-hFIX response. ODN activated monocyte-derived dendritic cells and enhanced T follicular helper cell responses. While depletion of regulatory T cells (Tregs) also caused an antibody response, TLR9 activation combined with Treg depletion instead resulted in prolonged CD8+ T cell infiltration of transduced muscle. Thus, Tregs modulate the response to the TLR9 agonist. Further, Treg re-population eventually resolved humoral and cellular immune responses. Therefore, specific modes of TLR9 activation and Tregs orchestrate antibody formation in muscle gene transfer.

SUBMITTER: Herzog RW 

PROVIDER: S-EPMC5794662 | biostudies-literature | 2019 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

Regulatory T cells and TLR9 activation shape antibody formation to a secreted transgene product in AAV muscle gene transfer.

Herzog Roland W RW   Cooper Mario M   Perrin George Q GQ   Biswas Moanaro M   Martino Ashley T AT   Morel Laurence L   Terhorst Cox C   Hoffman Brad E BE  

Cellular immunology 20170801


Adeno-associated viral (AAV) gene delivery to skeletal muscle is being explored for systemic delivery of therapeutic proteins. To better understand the signals that govern antibody formation against secreted transgene products in this approach, we administered an intramuscular dose of AAV1 vector expressing human coagulation factor IX (hFIX), which does not cause antibody formation against hFIX in C57BL/6 mice. Interestingly, co-administration of a TLR9 agonist (CpG-deoxyoligonucleotide, ODN) bu  ...[more]

Similar Datasets

| S-EPMC5142511 | biostudies-literature
| S-EPMC4754536 | biostudies-literature
| S-EPMC6923507 | biostudies-literature
| S-EPMC4417066 | biostudies-literature
| S-EPMC4172479 | biostudies-literature
| S-EPMC6299151 | biostudies-literature
| S-EPMC6903695 | biostudies-literature
| S-EPMC4395773 | biostudies-literature
| S-EPMC5476465 | biostudies-literature
| S-EPMC6881693 | biostudies-literature